Summary of Key Points from the Conference Call on Medical Devices and Brain-Computer Interfaces Industry Overview - The medical device sector is expected to see improvements in bidding processes in 2025, leading to stable or accelerated revenue growth for leading companies like United Imaging and Mindray in 2026. The new equipment update projects are set to be implemented in Q3 2025, suggesting a "front low, back high" growth pattern for next year's performance [1][2][3]. - The high-value consumables sector is anticipated to recover in valuation and performance due to optimized procurement policies, although the timing of performance turning points may vary among companies [1][3]. - The IVD (in vitro diagnostics) sector is expected to see a reduction in the impact of procurement policies by 2026, with companies like Mindray, New Industries, and United Imaging benefiting from enhanced product competitiveness and international market expansion [1][3]. Key Companies and Their Prospects - **Mindray Medical**: Currently at a long-cycle turning point, with positive revenue growth expected to continue. The company is transitioning from a device-centric model to focus more on IVD and other business lines, aiming to increase its overseas market share from over 40% to nearly 60% [1][7][8]. - **New Industries**: The company has seen its overseas business share rise to over 40%, maintaining a growth rate of 25%-30% annually, with a projected growth rate of 20%-25% for 2025. The gross margin for overseas revenue is also improving, from 50% in 2023 to 68% in the first half of 2025 [2][9]. - **Huatai Medical**: Expected to achieve significant revenue and net profit growth in 2026, particularly in its electrophysiology business, which is projected to see a substantial increase in procedure volumes due to procurement policy changes [1][14]. Investment Opportunities in Brain-Computer Interfaces (BCI) - The BCI sector is gaining traction as a significant investment area, with companies like Neuralink conducting clinical trials and advancing their technology. Domestic firms such as Xiangyu Medical and Sanbo Neuroscience are expected to accelerate their clinical trials and achieve more results in 2026 [2][4][18]. - Notable companies in the BCI field include **Micron Medical**, which has established a brain-machine research institute and reported a revenue of 760 million CNY in 2024, and **New Wei Medical**, which has turned profitable and is expected to see significant profit growth in the coming years [11][20]. Market Characteristics and Trends - The Hong Kong medical device sector is characterized by strong innovation, with many companies reaching a breakeven point and entering a phase of rapid profit release. Companies like MicroPort and MicroPort Robotics are highlighted as long-term investment opportunities [2][12]. - The low-value consumables sector is expected to grow steadily domestically, while international expansion will depend on the progress of domestic companies' overseas production capacity and changes in tariffs [17]. Conclusion - The medical device and BCI sectors are poised for recovery and growth, driven by policy improvements, strategic company adjustments, and international market expansion. Investors are encouraged to focus on companies with strong fundamentals and rapid commercialization processes, such as Mindray, Huatai Medical, and emerging players in the BCI space [2][24].

重要内容提示： | 回购方案首次披露日 | 2025/12/10，由公司董事会提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 9 10 | 12 | 月 | 日~2026 | 年 | 日 8 | | 预计回购金额 | 2亿元~2.5亿元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 402,976股 | | | | | | | 累计已回购股数占总股本比例 | 0.29% | | | | | | | 累计已回购金额 | 9,992.30万元 | | | | | | | 实际回购价格区间 | 235元/股~256元/股 | | | | | | 一、回购股份的基本情况 深圳惠泰医疗器械股份有限公司（以下简称"公司"）于 2025 年 12 月 9 日 召开第三届董事会第二次会议，审议通过了《关于以集中竞 ...

Group 1 - The company Huatai Medical announced on January 5 that it has repurchased approximately 400,000 shares through the Shanghai Stock Exchange, representing 0.29% of its total share capital of approximately 141 million shares [1] - The highest purchase price for the repurchased shares was 256 yuan per share, while the lowest was 235 yuan per share [1] - The total amount paid for the repurchased shares was approximately 99.923 million yuan [1] Group 2 - The iMaotai App saw a surge in popularity, reaching the top of the Apple shopping chart, with 10,000 users placing orders for the product [1] - The limited stock of 1,499 yuan Flying Moutai was sold out quickly, with 1,000 boxes being sold in a short period [1]

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

Core Viewpoint - Mindray Medical is facing temporary pressure in the domestic market due to multiple factors, but sees a historic opportunity for import substitution in the IVD market, aiming to double its market share in the next three years in the fields of chemiluminescence, biochemistry, and coagulation [1][3][4]. Market and Business Outlook - The domestic market has experienced a decline in capacity over the past two years, but the company believes this impact is temporary. The demand for quality improvement and cost control in medical institutions presents a significant opportunity for high-end breakthroughs and import substitution [3][4]. - The company expects positive growth in domestic business by 2026, with IVD leading the growth of three major product lines and emerging businesses achieving rapid growth [4]. Emerging Business Segments - Mindray's emerging businesses, including minimally invasive surgery, minimally invasive intervention, and animal healthcare, are projected to reach nearly 3.9 billion RMB in 2024, contributing over 10% to total revenue, and exceed 2.6 billion RMB in the first half of 2025, contributing over 15% [2][14]. - The minimally invasive surgery market is expected to grow significantly, with a projected market size of approximately 37.3 billion RMB in China by 2024, and a growth rate of 10.8% from 2024 to 2030 [15]. - The minimally invasive intervention market is also rapidly expanding, with a projected market size of approximately 32.5 billion RMB in China by 2024, driven by factors such as aging population and increasing prevalence of cardiovascular diseases [16]. Technological and Competitive Advantages - Mindray has established significant core advantages in the ultrasound market through nearly 30 years of investment, including a comprehensive product line, deep clinical insights, and a global platform [2][6][7]. - The company is leveraging AI technology and clinical expertise to create intelligent solutions that enhance operational efficiency and improve patient care [7][8]. Integration and Collaboration - The integration with Huatai Medical is progressing as planned, with a focus on enhancing operational efficiency and management standards while respecting the independence of Huatai [10][11]. - Mindray aims to deepen collaboration across various functions to strengthen Huatai's competitiveness in the cardiovascular field [11]. AI and Digital Solutions - Mindray's AI models have been successfully implemented in top hospitals, enhancing digital transformation and supporting precision medicine [12][13]. - The company is committed to integrating AI solutions with hardware and IT systems to maximize the effectiveness of its digital healthcare offerings [13].

Market Overview - The domestic market for medical devices has experienced a contraction over the past two years, impacting various business lines, although market share has been steadily increasing [2][3] - The IVD (In Vitro Diagnostics) sector is expected to lead growth among three major product lines, with significant market opportunities remaining, particularly in high-end hospital segments [3][4] Business Growth Projections - The domestic business is projected to achieve positive growth in 2026, with IVD driving this growth, while emerging businesses are expected to grow rapidly [3][4] - By 2024, the overall scale of emerging businesses is anticipated to reach approximately RMB 3.9 billion, contributing over 10% to total revenue [12][13] Competitive Landscape - The ultrasound imaging market is characterized by high specialization and significant barriers to entry, requiring extensive strategic investment and technological accumulation [4][5] - The entry of competitors like United Imaging is seen as a sign of a vibrant industry, with the market for ultrasound imaging expected to continue growing [4][5] Technological Innovations - The company has developed AI-driven solutions for chronic disease management, utilizing wearable sensors for continuous monitoring and data integration [6][7] - The launch of multiple AI models across various medical specialties has positioned the company as a leader in the medical AI domain, with applications in critical care and perioperative settings [10][11] Strategic Acquisitions - The integration of Huatai Medical is progressing as planned, with collaborative efforts in the cardiovascular field yielding positive results, including the development of a new atrial fibrillation solution [8][9] - The acquisition is expected to enhance the company's capabilities in the cardiovascular sector, leveraging existing strengths in medical imaging and diagnostics [15][16] Emerging Business Segments - The minimally invasive surgery market is projected to grow significantly, with a market size of approximately USD 33.8 billion globally and RMB 37.3 billion in China by 2024 [13][14] - The animal healthcare sector is also expanding, with a projected market size of nearly USD 4.4 billion in 2024, driven by the company's established technology and product offerings [16][17]

Group 1 - The core stock price of Huatai Medical (688617) closed at 250.54 yuan on December 26, 2025, down 1.55% from 254.49 yuan the previous week [1] - The highest intraday price for Huatai Medical during the week was 255.44 yuan, while the lowest was 243.49 yuan [1] - The current total market capitalization of Huatai Medical is 35.334 billion yuan, ranking 5th out of 127 in the medical device sector and 542nd out of 5178 in the A-share market [1] Group 2 - The fourth extraordinary general meeting of Huatai Medical for 2025 was held on December 25, 2025, with legal opinions provided by Beijing Jiayuan Law Firm [2] - The meeting, presided over by Chairman Ge Hao, utilized a combination of on-site and online voting, with a valid voting procedure [2][3] - A total of 275 shareholders attended the meeting, representing 62.4022% of the voting rights, and all proposed resolutions were passed without opposition or abstention [2][3]

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 针对上述提问，惠泰医疗回应称："尊敬的投资者，您好！公司在本次集采项目的中标事项不属于公司 应披露的重大事项。目前，公司不存在应披露而未披露信息。感谢您的关注！" 来源：市场资讯 有投资者在互动平台向惠泰医疗提问："请问，贵公司在2025年12月北京医保局电生理类集采中标了为 什么不公告出来，谢谢！！！" ...

（文章来源：证券日报） 证券日报网讯 12月25日，惠泰医疗发布公告称，公司2025年12月25日召开2025年第四次临时股东会， 审议通过《关于2026年度日常关联交易预计的议案》等。 ...

北京市嘉源律师事务所 关于深圳惠泰医疗器械股份有限公司 2025年第四次临时股东会的法律意见书 嘉源(2025)-04-952 北京市嘉源律师事务所(以下简称"本所")接受深圳惠泰医疗器械股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》")、《上市公司股东会规则》(以下简称"《股东会规则》")等现行有 效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及《深 圳惠泰医疗器械股份有限公司章程》(以下简称"《公司章程》")的有关规定,指 派本所律师对公司 2025年第四次临时股东会(以下简称"本次股东会")进行见 证,并依法出具本法律意见书。 北京市嘉源律师事务所 关于深圳惠泰医疗器械股份有限公司 2025年第四次临时股东会的法律意见书 西城区复兴门内大街158 号远洋大厦 4 楼 中国 · 北京 T CUMERS Pr YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:深圳惠泰医疗器械股份有限公司 一、本 ...